αvβ6 peptide ligands and their uses
AVβ6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AVβ6 mediated diseases.
1. A peptide the amino acid sequence of which consists of B n RGDLX 5 X 6 LX 8 X 9 X 10 Z m X i , wherein LX 5 X 6 L has an alpha helical structure, B n is a sequence of n amino acids each of which is any amino acid, X 5 , X 6 , X 8 , X 9 and X 10 each independently represent any amino acid, each Z is a helix promoting residue independently selected from the group consisting of Glu, Ala, Leu, Met, Gln, Lys, Arg, Val, Ile, Trp, Phe and Asp, X i , is a sequence of i amino acids each of which is any amino acid, m is at least 1, n is 6 to 7, and n, m and i are selected to make the maximum length of said peptide 20 amino acids, said peptide having a modification selected from the group consisting of:
(i) linkage to at least one non-peptide therapeutically active moiety;
(ii) linkage to at least one readily detectable moiety;
(iii) linkage to at least one nanoparticle;
(iv) linkage to at least one lipid-based vesicle;
(v) linkage to at least one capping residue; and
(vi) replacement of at least one amino acid residue of said peptide with at least one of a halide derivative thereof or a N or C alkyl substituted form thereof or a combination of said derivative and said substituted form.
2. A peptide selected from the group consisting of A20FMDV1 (SEQ ID NO: 7) and A20LAP (SEQ ID NO: 6).
3. The peptide A20FMDV2(SEQ ID NO: 8).
4. A peptide the amino acid sequence of which consists of B n RGDLX 5 X 6 IX 8 X 9 X 10 Z m X i , wherein LX 5 X 6 I has an alpha helical structure, B n is a sequence of n amino acids each of which is any amino acid, X 5 , X 6 , X 8 , X 9 and X 10 each independently represent any amino acid, each Z is a helix promoting residue independently selected from the group consisting of Glu, Ala, Leu, Met, Gln, Lys, Arg, Val, Ile, Trp, Phe and Asp, X I , is a sequence of i amino acids each of which is any amino acid, m is at least 1, n is 6 to 7, and n, m, and i are selected to make the length of said peptide 20 amino acids, said peptide having a modification selected from the group consisting of:
(i) linkage to at least one non-peptide therapeutically active moiety;
(ii) linkage to at least one readily detectable moiety;
(iii) linkage to at least one nanoparticle;
(iv) linkage to at least one lipid-based vesicle;
(v) linkage to at least one capping residue; and
(vi) replacement of at least one amino acid residue of said peptide with at least one of a halide derivative thereof or a N or C alkyl substituted form thereof or a combination of said derivative and said substituted form.
5. The peptide of claim 1 , 2 , 3 , or 4 , wherein the peptide is linked to a non-peptide therapeutically active moiety.
6. The peptide of claim 5 , wherein the therapeutically active moiety is an anti-cancer agent.
7. The peptide of claim 1 , 2 , 3 , or 4 , wherein the peptide is linked to a readily detectable moiety.
8. The peptide of claim 7 , wherein the readily detectable moiety is a radioactive moiety.
9. A pharmaceutical composition comprising the peptide of claim 1 , 2 , 3 , or 4 , and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the peptide of claim 5 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising the peptide of claim 7 and a pharmaceutically acceptable carrier.